By continuing to use the site, you allow the use of Cookies and agree to the privacy policy.
.,о.,р..и.:г,.и.,н.;н.,а;,л.. .,н.:а,.х.,о.,д.;и.,т..с.:я,, ..н.;а., .,k;,i..b.:e,;r.,i.,s.,.;.r.:u,

Antitumor agents - monoclonal antibodies

Pharmaceutical group preparations

Substance Drugs
Atezolizumab
Avelumab
Bevacizumab | | |
Blinatumomab
Catumaxomab
Cetuximab |
Daratumumab
Dinutuximab beta
Durvalumab
Elotuzumab
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Ipilimumab
Isatuximab
Natalizumab
Nivolumab
Obinutuzumab |
Ofatumumab |
Olaratumab
Panitumumab
Pembrolizumab |
Pertuzumab
Polatuzumab vedotin
Prolgolimab
Ramucirumab
Rituximab | | | |
Trastuzumab | | |
Trastuzumab deruxtecan
Trastuzumab emtansine
The active substance is not described | | | | |

Tree of pharmacological groups

Description

There is no detailed description, see related
42a96bb5c8a2acfb07fc866444b97bf1
Available only when using PRO account
Content moderator: Vasin A. S.